Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial

類似資料

• Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial
  著者:: Ma, Jianhui, 等
  出版事項: (2020)
• Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
  著者:: Xinan Sheng, 等
  出版事項: (2020-03-01)
• Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
  著者:: Sheng, Xinan, 等
  出版事項: (2020)
• Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib
  著者:: Keizman, Daniel, 等
  出版事項: (2016)
• The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma
  著者:: Song, Yan, 等
  出版事項: (2021)